Molgramostim Inhalation Solution

Name: Molgramostim Inhalation Solution in Autoimmune pulmonary alveolar proteinosis: Pathophysiology
Published: 2026-09-14T15:39:06-04:00

Autoimmune pulmonary alveolar proteinosis

Manufacturer: Savara
Regulatory submission: BLA resubmitted December 2025
Launch: Not announced
Last updated: September 19, 2026

Section

Product information and disease description Place of product in therapy Disease description

Pathophysiology

1 evidence topic · 2 sources

GM-CSF autoantibodies

“Pathogenesis is driven by GM-CSF (granulocyte/macrophage colony-stimulating factor) autoantibodies, which are present at high concentrations in blood and tissues” (opens the source at this quote in a new tab)